Banco BBVA Argentina Shows Early Recovery but Group Thesis Unchanged

What happened

Banco BBVA Argentina S.A. reported a Q2 ROE of 12.2% and strengthening fee income, with management guiding to 10% real loan growth in 2026 and aiming to outpace the market on the back of strong liquidity and capital. However, credit quality remains a key risk, as the NPL ratio stands at 6.09% and the projected 2026 cost of risk is 6.5%, even as some metrics stabilize. This subsidiary update adds a modest positive datapoint for BBVA's South American franchise but does not materially move the group-level investment case, which is dominated by Spain and Mexico and trades near $23.72 with a WAIT rating. The group's own recent filings already highlight a 2.8% group NPL ratio and 1.35% group cost of risk, so Argentina's much higher risk profile underscores the need for sustained improvement before it can be considered a credible earnings driver. Overall, the article provides early signs of recovery in Argentina but lacks sufficient evidence to shift the cautious stance on BBVA as a whole.

Implication

Investors should treat the Argentina update as an early-stage positive signal that requires several more quarters of confirmation, given the still-elevated NPL ratio and assumed 6.5% cost of risk. The parent's WAIT rating remains appropriate because the primary value drivers are Spain and Mexico, where macroeconomic and FX risks dominate, and the group trades at a premium multiple after a 137% rally. A sustained improvement in Argentina's ROE and a decisive decline in its cost of risk could, over time, add modest upside to group earnings, but it is not a near-term catalyst. The more critical monitorables remain Mexico's cost of risk, MXN stability, and execution of BBVA's large buyback and distribution plan. We would only consider upgrading the view on the back of group-level evidence, such as CET1 holding above 12.3% and demonstrated delivery toward the €48B profit target, not on subsidiary-level optimism.

Thesis delta

The news from Banco BBVA Argentina does not change the overall WAIT thesis on BBVA. It adds a minor positive for a non-core subsidiary, but the group investment case remains driven by Spain and Mexico, where valuation after a 137% rally leaves little margin for error. The thesis shift is negligible: we continue to see better risk-adjusted entry near $20 or after clearer group-level delivery.